The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer

British Journal of Cancer

Volumn 94, Issue 12, 2006, Pages 1833-1836

  Crozier, J E M ^a   McKee, R F ^a   McArdle, C S ^a   Angerson, W J ^a   Anderson, J H ^a   Horgan, P G ^a   McMillan, D C ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

5 FU adjuvant chemotherapy; Albumin; C reactive protein; Colorectal cancer; Dukes stage; Survival

Indexed keywords

C REACTIVE PROTEIN; FLUOROURACIL;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; COLORECTAL CANCER; CONCENTRATION (PARAMETERS); DEATH; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; C-REACTIVE PROTEIN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; FLUOROURACIL; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 33745061680     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603185     Document Type: Article

References (26)

1. Andreyev HJ, Norman AR, Oates J, Cunningham D (1998) Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 34: 503-509
2. Baker SD, van Schaik RH, Rivory LP, Ten Tije AJ, Dinh K, Graveland WJ, Schenk PW, Charles KA, Clarke SJ, Carducci MA, McGuire WP, Dawkins F, Gelderblom H, Verweij J, Sparreboom A (2004) Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 10: 8341-8350
3. Benson III AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers M, Charette M, Haller DG (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22: 3408-3419
4. Bromwich E, McMillan DC, Lamb GW, Vasey PA, Aitchison M (2004) The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer. Br J Cancer 91: 1236-1238
5. Canna K, McArdle PA, McMillan DC, McNicol AM, Smith GW, McKee RF, McArdle CS (2005) The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 92: 651-654
6. Cascinu S, Georgoulias V, Kerr D, Maughan T, Labianca R, Ychou M (2003) Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors. Ann Oncol 14(Suppl 2): ii25-ii29
7. Cengiz M, Akbulut S, Atahan IL, Grigsby PW (2001) Acute phase response during radiotherapy. Int J Radiat Oncol Biol Phys 49: 1093-1096
8. Dukes CE, Bussey HJR (1958) The spread of rectal cancer and its effect on prognosis. Br J Cancer 12: 309-320
9. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2004) Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 90: 1704-1706
10. Jass JR, Love SB, Northover JM (1987) A new prognostic classification of rectal cancer. Lancet 1(8545): 1303-1306
11. Koc M, Taysi S, Sezen O, Bakan N (2003) Levels of some acute-phase proteins in the serum of patients with cancer during radiotherapy. Biol Pharm Bull 26: 1494-1497
12. Lundholm K, Gelin J, Hyltander A, Lonnroth C, Sandstrom R, Svaninger G, Korner U, Gulich M, Karrefors I, Norli B (1994) Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 54: 5602-5606
13. McArdle CS, Hole DJ (2002) Outcome following surgery for colorectal cancer: analysis by hospital after adjustment for case-mix and deprivation. Br J Cancer 86: 331-335
14. McMillan DC, Canna K, McArdle CS (2003) A systemic inflammatory response predicts survival following curative resection for colorectal cancer. Br J Surg 90: 215-219
15. McMillan DC, Wigmore SJ, Fearon KC, O'Gorman P, Wright CE, McArdle CS (1999) A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 79: 495-500
16. McMillan DC, Wotherspoon HA, Fearon KC, Sturgeon C, Cooke TG, McArdle CS (1995) A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery. Am J Surg 170: 319-322
17. Nielsen HJ, Christensen IJ, Sorensen S, Moesgaard F, Brunner N (2000) Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol 7: 617-623
18. Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brunner N, Moesgaard F, The RANX05 Study Group (1999) Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol 189: 487-495
19. O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, Wieand HS (1997) Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15(1): 246-250
20. O'Gorman P, McMillan DC, McArdle CS (1999) Longitudinal study of weight, appetite, performance status, and inflammation in advanced gastrointestinal cancer. Nutr Cancer 35: 127-129
21. O'Gorman P, McMillan DC, McArdle CS (2000) Prognostic factors in advanced gastrointestinal cancer patients with weight loss. Nutr Cancer 37: 36-40
22. Rivory LP, Slaviero KA, Clarke SJ (2002) Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer 87: 277-280
23. Salmon JS, Lockhart AC, Berlin J (2005) Anti-angiogenic treatment of gastrointestinal malignancies. Cancer Invest 23: 712-726
24. Scottish Cancer Intelligence Unit (2000) Trends in Cancer Survival in Scotland 1971-1995 Information and Statistics Division. Edinburgh: Common Services Agency, pp 54-71
25. Slaviero KA, Clarke SJ, Rivory LP (2003) Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 4: 224-232
26. Xavier P, Belo L, Beires J, Rebelo I, Martinez-de-Oliveira J, Lunet N, Barros H (2006) Serum levels of VEGF and TNF-alpha and their association with C-reactive protein in patients with endometriosis. Arch Gynecol Obstet 273: 227-231